Deleterious variants in the BRCA1/BRCA2 genes and homologous recombination deficiency (HRD) status are considered strong predictors of response to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Here, BRCA1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.